NCT06855121 The Norwegian Immunotherapy in Multiple Myeloma Study
| NCT ID | NCT06855121 |
| Status | Recruiting |
| Phase | — |
| Sponsor | St. Olavs Hospital |
| Condition | Myeloma Multiple |
| Study Type | OBSERVATIONAL |
| Enrollment | 400 participants |
| Start Date | 2025-01-15 |
| Primary Completion | 2029-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 400 participants in total. It began in 2025-01-15 with a primary completion date of 2029-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this observational study is to study the effectiveness and complications of novel immunotherapies used in the treatment of multiple myeloma in routine care in Norway. The aim is to close knowledge gaps, generate evidence for future clinical trials and contribute to future consensus on how to monitor for adverse events, and what mitigation strategies should be implemented, so that we can increase patient survival and quality-of-life.
Eligibility Criteria
Inclusion criteria * Participants age ≥ 18 years * Prior diagnosis of one of the following * Multiple myeloma as defined according to IMWG criteria * Primary plasma cell leukemia as defined according to IMWG consensus definition * AL-amyloidosis as defined according to IMWG criteria * Planned treatment with one of the following outside clinical trials (list to be amended based on approvals within the EU): * Teclistamab (Tecvayli) * Elranatamab (Elrexfio) * Talquetamab (Talvey) * Idecabtagene vicleucel (ide-cel/Abecma) * Ciltacabtagene autoleucel (cilta-cel/Carvykti) Exclusion Criteria: * None
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06855121 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Myeloma Multiple. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06855121 currently recruiting?
Yes, NCT06855121 is actively recruiting participants. Contact the research team at tobias.s.slordahl@ntnu.no for enrollment information.
Where is the NCT06855121 trial being conducted?
This trial is being conducted at Arendal, Norway, Ålesund, Norway, Bergen, Norway, Bodø, Norway and 11 additional locations.
Who is sponsoring the NCT06855121 clinical trial?
NCT06855121 is sponsored by St. Olavs Hospital. The trial plans to enroll 400 participants.